$TCMD

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Rating of "Moderate Buy" from Analysts

Tactile Systems Technology, Inc. (NASDAQ:TCMD) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $38.60. Despite missing EPS estimates, the company exceeded revenue expectations in its latest quarter. Insider selling was observed, but institutional ownership remains high, with several major funds increasing or establishing positions.

Original reporting
MarketBeat · MarketBeat
Published May 8, 2026, 6:56 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 8, 2026, 7:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Rating of "Moderate Buy" from Analysts — source image
Decision brief

The 30-second read

$TCMDBullishMed
01

Why it matters

The analyst consensus and institutional interest indicate positive sentiment, but earnings miss and insider selling introduce some uncertainty.

02

Market read

The news is highly relevant for investors in the healthcare device sector and those holding or considering TCMD shares.

03

What to watch

Potential upcoming regulatory changes or sector-wide shifts that could impact performance are not discussed.

Timing: Short to medium term (1-3 months)

Background

Tactile Systems Technology, Inc. specializes in medical devices for vascular and lymphedema conditions. Recent earnings reports show mixed results, with revenue exceeding expectations but EPS missing estimates.

Company-level read

Ticker impact

$TCMDBullishMedium confidence
Context

High relevance due to analyst ratings and institutional activity.

Expected impact

Moderate upward movement within the next 1-3 months, approximately 10-15% increase.

Evidence & confidence

Analyst consensus and institutional buying support positive outlook, but earnings miss and insider selling introduce some risk.

Market effects

Potential positive influence on the medical device and life sciences sectors due to company-specific developments.

Limited regional impact; primarily affects investors focused on US markets.

Minimal global market impact given company size and sector.

Counterpoint

The earnings miss and insider selling could signal underlying issues, suggesting caution against aggressive buying.

Key entities

  • Tactile Systems Technology, Inc.

    A medical device company focusing on vascular and lymphedema treatment devices.

Related articles

$TCMDHigh

TACTILE SYSTEMS TECHNOLOGY INC (TCMD): Results of Operations and Financial Condition

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tcmd-20260810xex99d1.htm EX-99.1 Exhibit 99.1 Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results MINNEAPOLIS, MN, August 10th, 2026 – Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology com

$TCMDMedAI 8/10

Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy

Tactile Medical (Nasdaq: TCMD) announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation system. The company says it keeps the same use for chronic neuromuscular and respiratory conditions such as cystic fibrosis and bronchiectasis across ages, while adding a lighter, more adjustable vest and a redesigned controller. It also includes built-in Wi‑Fi/Bluetooth for connected care and clinician/payer data.

$DISMed

Disney, Comcast reach deal, lifting NFL Network blackout

Comcast and Disney reached an agreement to end the NFL Network blackout for Comcast Xfinity TV subscribers, resuming NFL Network and NFL RedZone in time for the 2026 season. The blackout began after their contract expired in late April. Disney owns 72% of ESPN, which took over NFL Media assets earlier this year. Terms were not disclosed.

$ABUSMed

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

Arbutus Biopharma (ABUS) received about $178 million from Moderna (MRNA) as its share of a $950 million noncontingent LNP patent settlement, with reimbursement of legal costs and an expected Q3 dividend tied to Genevant. ABUS reported Q1 2026 revenue of $179.1 million and net income of $169.7 million. Moderna reported Q2 2026 revenue of $145 million and a net loss of $782 million, plus FDA approval for mFLUSIVA.

$IONQMedAI 8/10

Pentagon may see one of quantum computing’s first practical winners

IonQ (IONQ) said DARPA awarded a $28 million contract modification under its It’s About Time program to support production development and 25 Evergreen-05 optical atomic clocks, with a $30 million option for 100 additional clocks. IonQ plans to invest $15 million to scale manufacturing. The company cites timing performance for GPS-denied defense uses.

$CCEYFMedAI 8/10

CanCambria Energy Provides Updated Contingent Resource Evaluation for Flagship Deep Gas Project, Attributable to Strong European Natural Gas Prices, Driving an Increased NPV10 of US$2.04 Billion

CanCambria Energy Corp. (TSXV: CCEC) reported an updated independent contingent resource evaluation for its 100% owned Kiskunhalas deep gas project in southern Hungary. Prepared by CHPE (effective June 30, 2026), it assumes $12.00/MMBtu TTF1 gas. Risked 2C Development Pending NPV10 rose 16% to US$2.04B from US$1.762B; 2C volumes are 571.9 Bcf and 59.6 MMbbl. First gas is targeted for mid-2027.